International Immunology, Vol. 11, No. 2, 289-296,
February 1999
© 1999 Japanese Society for Immunology
Non-coding plasmid DNA induces IFN-
in vivo and suppresses autoimmune encephalomyelitis
1 The Weizmann Institute of Science, Department of Immunology, Rehovot 76100, Israel
2 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 943055429, USA
Correspondence to: L. Steinman, Department of Neurology and Neurological Sciences, Beckman B002, Stanford University School of Medicine, Stanford, CA 94305-5429, USA
Regulatory sequences used in plasmids for naked DNA vaccination can modulate cytokine production in vivo. We demonstrate here that injection of plasmid DNA can suppress the prototypic T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis, by inducing IFN-
.
Keywords: autoimmunity, cytokines, experimental autoimmune encephalomyelitis, gene therapy, multiple sclerosis, vaccination
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. T. Tigno-Aranjuez, R. Jaini, V. K. Tuohy, P. V. Lehmann, and M. Tary-Lehmann Encephalitogenicity of Complete Freund's Adjuvant Relative to CpG Is Linked to Induction of Th17 Cells J. Immunol., November 1, 2009; 183(9): 5654 - 5661. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Marsh, S. L. Stevens, B. Hunter, and M. P. Stenzel-Poore Inflammation and the Emerging Role of the Toll-Like Receptor System in Acute Brain Ischemia Stroke, March 1, 2009; 40(3_suppl_1): S34 - S37. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Krieg Antiinfective Applications of Toll-like Receptor 9 Agonists Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Okura, A. Miyakoshi, K. Kohyama, I.-K. Park, M. Staufenbiel, and Y. Matsumoto Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: Long-term effects and safety PNAS, June 20, 2006; 103(25): 9619 - 9624. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Ho, P. Fontoura, P. J. Ruiz, L. Steinman, and H. Garren An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems J. Immunol., November 1, 2003; 171(9): 4920 - 4926. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Quintana, A. Rotem, P. Carmi, and I. R. Cohen Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity J. Immunol., December 1, 2000; 165(11): 6148 - 6155. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lobell, R. Weissert, S. Eltayeb, C. Svanholm, T. Olsson, and H. Wigzell Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis J. Immunol., November 1, 1999; 163(9): 4754 - 4762. [Abstract] [Full Text] [PDF] |
||||



